Is there a rationale to supplement hepatotropic factors to dogs with multiple acquired portosystemic shunts secondary to congenital portosystemic shunt attenuation?

Autor:	L. Van Acker, W. De Spiegelaere, Dominique Paepe, Nausikaa Devriendt, H. de Rooster, Goncalo Serrano
Rok vydání:	2021
Předmět:	medicine.medical_specialty Cirrhosis General Veterinary business.industry Rat model medicine.disease Gastroenterology Clinical trial Animal proteins Internal medicine medicine Hepatocyte growth factor Liver function Portosystemic shunt business Pathological medicine.drug
Zdroj:	Vlaams Diergeneeskundig Tijdschrift. 90:209-215
ISSN:	0303-9021
DOI:	10.21825/vdt.v90i4.20717
Popis:	Experimental rat models and clinical trials in human patients with liver cirrhosis show evidence that supplementation with hepatotropic factors provides therapeutic benefits. This form of support has not yet been described in dogs with multiple acquired portosystemic shunts (MAPSS) despite similarities between both pathological conditions. Especially hepatocyte growth factor (HGF) and branched chain amino acids (BCAA) deserve closer attention. High-quality vegetable rather than animal proteins have been suggested to form an excellent dietary source of BCAA, and leucine seems the best candidate for supplementation given its stimulating effects on liver function in general and on HGF secretion specifically. Research on optimal ways of administration of HGF in dogs with MAPSS secondary to congenital portosystemic shunt attenuation is necessary before clinical trials can be initiated.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4b2ef9c08a126ddc1e5867ab64feba31 https://doi.org/10.21825/vdt.v90i4.20717 Zobrazit plný text záznamu